glp 1 blue cross blue shield Why is rolling back coverage of GLP-1 weight loss drugs in Massachusetts Why we are changing coverage

Doubling the receptor load makes them potentially unmanageable

This phenomenon may be the result of its unbalanced dual agonistic effect, favoring GIPR over GLP-1R activity [7], because dose escalation of selective GLP-1R agonists induces undesirable gastrointestinal effects

These results follow similar findings from the companys ATTAIN-1 trial released earlier this month, which tested the drug on people who were overweight or obese without type 2 diabetes (in general, people without diabetes tend to lose more weight from GLP-1 therapy than those with diabetes)

Keep it realistic: Half-dosing might save a few bucks in the short term, but if you lose the meds full benefits, you might end up back at square one

Follow the updated guidance for pausing medication